

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:	A 1	(11) International Publication Number: WO 97/48720
C07H 21/04, C12N 15/09, 15/79, A61K 31/70	A1	(43) International Publication Date: 24 December 1997 (24.12.97
(21) International Application Number: PCT/US97/10486 (22) International Filing Date: 17 June 1997 (17.06.97)		CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL
(30) Priority Data: 60/019,808 17 June 1996 (17.06.96)	ι	Published S With international search report.
(71) Applicant (for all designated States except US): FOX CANCER CENTER [US/US]; 7701 Burhome Philadelphia, PA 19111 (US).	CHAS Avenu	E .
(72) Inventors; and (75) Inventors/Applicants (for US only): TSICHLIS [US/US]; 50 Brentwood Avenue, Willow Ave 19090 (US). GRIMES, H., Leighton, III [US/US] ment 22, 1 Christian Street, Philadelphia, PA 191 ZWEIDLER-McKAY, Patrick [US/US]; 2nd f Cameron Avenue, West Somerville, MA 02144-24	nue, P]; Apa 147 (US floor, (A
(74) Agents: REED, Janet, E. et al.; Dann, Dorfman, F. Skillman, Suite 720, 1601 Market Street, Philadel 19103 (US).		

(54) Title: NUCLEIC ACID MOLECULE FOR ENHANCING GENE EXPRESSION

(57) Abstract

Novel nucleic acid molecules are provided comprising a mutated promoter sequence, preferably a mutated human cytomegalovirus promoter sequence, which is no longer recognized by the Gfi-1 transcriptional repressor. Loss of repressor recognition results in augmented gene expression in recombinant vectors containing this promoter. The promoter may be used to enhance production levels of clinically beneficial proteins in cells transformed therewith. These vectors can be used for the generation of constructs for use in gene therapy and as DNA vaccines.